# Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide

> **NCT04694586** · PHASE2 · SUSPENDED · sponsor: **University Hospital, Linkoeping** · enrollment: 40 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** rifampicin
- **DRUG:** pyrazinamide
- **DRUG:** HRZE
- **DRUG:** HR

## Key facts

- **NCT ID:** NCT04694586
- **Lead sponsor:** University Hospital, Linkoeping
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-11-30
- **Primary completion:** 2024-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** Suspended 15th of Nov 2023 due to conditions affecting recruitment process.
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04694586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04694586, "Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04694586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*